MedPath

Research on the Accurate Diagnosis of Urinary Tract Tumors and the Development of Kits

Completed
Conditions
Bladder Cancer
Urothelial Carcinoma
Interventions
Diagnostic Test: RT-qPCR
Registration Number
NCT06193941
Lead Sponsor
Zhongnan Hospital
Brief Summary

Bladder cancer is the second most prevalent urological malignancy worldwide, with a high incidence and poor patient prognosis. Achieving early diagnosis and intervention for bladder cancer is one of the most important ways to improve clinical management and patient prognosis. Tumor exosomes can be released into biological fluids at an early stage of a tumor, and many studies have shown that exosomal RNA can be used as a reliable biomarker to diagnose tumors in a non-invasive way. Based on the clinical needs for early diagnosis of bladder cancer, we aim to screen several early diagnostic markers with potential predictive value, establish an early diagnostic model for bladder cancer, and validate the validity and reliability of this diagnostic model through a large-scale clinical cohort to complement the diagnosis of early-stage cancers and to improve the rate of early diagnosis of cancer.

Detailed Description

In response to the clinical demand for accurate early diagnosis of bladder cancer, this project aims to gradually conduct in-depth research on precise early diagnosis of bladder cancer. This includes establishing key techniques for efficient and convenient enrichment of exosomes, identifying potential exosome biomarkers for bladder cancer based on bladder cancer transcriptome sequencing data, and conducting large-scale clinical cohort studies.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
400
Inclusion Criteria
  1. Age ≥ 18 years with defined gender;
  2. Preoperative patients are preliminarily evaluated as bladder tumors by cystoscopy, FISH, cytology, or imaging.
Exclusion Criteria
  1. Aged <18 years;
  2. Post-operative or after anti-tumor treatment such as chemotherapy or immunotherapy
  3. History of other malignant tumors
  4. Specimens with hemolytic conditions;
  5. Patients with incomplete, undocumented, and uncooperative data.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Healthy people groupRT-qPCRUrine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
Control group (benigh)RT-qPCRUrine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
Case group (bladder cancer)RT-qPCRUrine exosomes were enriched for RT-qPCR within 4 hours after samples were collected.
Primary Outcome Measures
NameTimeMethod
RT-qPCRUrine exosomes were enriched for RT-qPCR within 4 hours after the samples were collected.

Urine exosomal RNA

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Zhongnan Hospital of Wuhan University

🇨🇳

Wuhan, Hubei, China

© Copyright 2025. All Rights Reserved by MedPath